Status and phase
Conditions
Treatments
About
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria (all groups):
Inclusion (group mild, moderate and severe hepatic impairment):
-Subjects with confirmed cirrhosis
Exclusion (all groups):
Exclusion for moderate, mild and severe groups:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
33 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal